Immunotherapy Monitoring

The development of methods to propagate immune T-cells, and in particular tumor specific T-cells from the patients with cancer, lead to an important breakthrough; the identification of MAGE-1,a melanoma-specific antigen that stimulates human T-cells in-vitro. With antigen specific T-cells as a reagents, it was possible to clone the MAGE-1 studies showed that the human immune system can respond tumor antigens, and the findings stimulated a productive effort to discover tumor antigens. The result is a long and still-growing list of antigens from a variety of tumor that could serve a variety of tumor’s that could serve as targets for treatment.

    Related Conference of Immunotherapy Monitoring

    April 04-05, 2024

    38th International Conference on Immunology

    Madrid, Spain
    May 23-24, 2024

    18th International Conference on European Immunology

    Zurich, Switzerland

    Immunotherapy Monitoring Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in